These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 576837)

  • 61. Influence of strain and age on the induction of mammary tumours by diethylstilboestrol in C3H mice.
    Greenman DL; Kodell RL; Highman B; Schieferstein GJ; Norvell M
    Food Chem Toxicol; 1984 Nov; 22(11):871-4. PubMed ID: 6542052
    [TBL] [Abstract][Full Text] [Related]  

  • 62. U.S. Food and Drug Administration requirements for toxicity testing of contraceptive products.
    Berliner VR
    Acta Endocrinol Suppl (Copenh); 1974; 185():240-65. PubMed ID: 4206185
    [No Abstract]   [Full Text] [Related]  

  • 63. Hormone and drug effects on growth of DMBA mammary tumours and plasma prolactin levels in adreno-ovariectomized rats.
    Minasian-Batmanian LC; Jabara AG
    Br J Cancer; 1981 Jun; 43(6):832-41. PubMed ID: 6788061
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Influence of norethynodrel and mestranol upon cervical dysplasia and carcinoma in situ.
    Ayre JE; Hillemanns HG; Le GUERRIER J; Leguerrier J; Arsenault J
    Obstet Gynecol; 1966 Jul; 28(1):90-8. PubMed ID: 5940458
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Thromboembolic disease associated with norethynodrel: report of six cases.
    Schatz IJ; Smith RF; Breneman GM; Bower GC
    JAMA; 1964 May; 188(6):493-5. PubMed ID: 12255392
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man.
    Tolis G; Pinter EJ; Friesen HG
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):281-3. PubMed ID: 1165136
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hormonally induced renal neoplasia in the male Syrian hamster and the inhibitory effect of 2-bromo-alpha-ergocryptine methanesulfonate.
    Hamilton JM; Flaks A; Saluja PG; Maguire S
    J Natl Cancer Inst; 1975 Jun; 54(6):1385-400. PubMed ID: 166190
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition by caffeine of ovarian hormone-induced mammary gland tumorigenesis in female GR mice.
    VanderPloeg LC; Welsch CW
    Cancer Lett; 1991 Mar; 56(3):245-50. PubMed ID: 2021928
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of estrogen on glucose tolerance.
    Buchler D; Warren JC
    Am J Obstet Gynecol; 1966 Jun; 95(4):479-83. PubMed ID: 5939015
    [No Abstract]   [Full Text] [Related]  

  • 70. Effect of 2-bromo-alpha-ergocryptine (CB 154) on plasma prolactin, LH and testosterone levels, accessory reproductive glands and spermatogenesis in lambs during puberty.
    Ravault JP; Courot M; Garnier D; Pelletier J; Terqui M
    Biol Reprod; 1977 Sep; 17(2):192-7. PubMed ID: 578119
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mammary tumor induction in ACI rats exposed to low levels of 17beta-estradiol.
    Ravoori S; Vadhanam MV; Sahoo S; Srinivasan C; Gupta RC
    Int J Oncol; 2007 Jul; 31(1):113-20. PubMed ID: 17549411
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17beta-oestradiol and testosterone.
    Xie B; Tsao SW; Wong YC
    Carcinogenesis; 1999 Jun; 20(6):1069-78. PubMed ID: 10357790
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Associated effects of bromocriptine on neoplastic progression of mouse mammary preneoplastic hyperplastic alveolar nodule line C4 and on hyperplastic alveolar nodule-infiltrating and splenic lymphocyte function.
    Tsai SJ; Loeffler DA; Heppner GH
    Cancer Res; 1992 Apr; 52(8):2209-15. PubMed ID: 1559224
    [TBL] [Abstract][Full Text] [Related]  

  • 74. N-nitroso-N-methylurea-induced mammary tumors in the rat: role of prolactin and a prolactin-lowering drug.
    Gandilhon P; Mélançon R; Djiane J; Kelly PA
    J Natl Cancer Inst; 1983 Jan; 70(1):105-9. PubMed ID: 6296514
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibition of mammary tumorigenesis in nulliparous C3H mice by chronic feeding of the synthetic retinoid, N-(4-hydroxyphenyl)-retinamide.
    Welsch CW; DeHoog JV; Moon RC
    Carcinogenesis; 1983 Sep; 4(9):1185-7. PubMed ID: 6224605
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acceptability of oral contraceptives.
    Med Gynaecol Sociol; 1966; 1(2):10. PubMed ID: 12305328
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reduced beta adrenergic responsiveness in rats treated with estrogenic agents.
    Black DJ; Fregly MJ; Thrasher TN; Moreland AF
    J Pharmacol Exp Ther; 1976 May; 197(2):362-70. PubMed ID: 1271285
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term effects of neonatal treatment with progesterone, alone and in combination with estrogen, on the mammary gland and reproductive tract of female BALB/cfC3H mice.
    Jones LA; Bern HA
    Cancer Res; 1977 Jan; 37(1):67-75. PubMed ID: 830422
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of perinatal exposure to a synthetic estrogen and progestin on mammary tumorigenesis in mice.
    Lopez J; Ogren L; Verjan R; Talamantes F
    Teratology; 1988 Aug; 38(2):129-34. PubMed ID: 3175946
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Metabolism of prolactin in mice with a high incidence of mammary tumours: evidence for greater conversion into a non-immunoassayable form.
    Sinha YN; Baxter SR
    J Endocrinol; 1979 Jun; 81(3):299-314. PubMed ID: 469461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.